Publications

Tsai KK, Chang AY, Abouzeid CM, Aras MA, Fang Q, Bibby D, Haghighat L, Hilton JF, Daud AI, Schiller NB. Longitudinal Evaluation of Immune Checkpoint Inhibitor-Induced Fatigue Syndrome by Rest, Stress, and Speckle-Tracking Strain Echocardiography. Echocardiography (Mount Kisco, N.Y.). 2025. PMID: 40198654

Gilligan T, Lin DW, Adra N, Bagrodia A, Feldman DR, Yamoah K, Aggarwal R, Chandrasekar T, Costa D, Drakaki A, Eggener S, Emamekhoo H, Geynisman DM, Graham L, Humphrey P, Leuva H, Levine EG, Luckenbaugh A, Maughan BL, McGregor B, Monk P, Picus J, Pierorazio P, Rais-Bahrami S, Reichert Z, Rwigema JC, Saylor P, Shah A, Shah S, Singla N, Sircar K, VanderWeele D, Zhumkhawala A, Montgomery S, Sliker B. NCCN Guidelines® Insights: Testicular Cancer, Version 2.2025. Journal of the National Comprehensive Cancer Network : JNCCN. 2025. PMID: 40203876

Feng EM, Vo-Phamhi J, Subramanian AN, Dias M, Foye A, Vinson J, Hong JC, Freedland SJ, Alumkal JJ, Beltran H, Morrissey C, Nelson PS, Chinnaiyan AM, Aggarwal R, Small EJ, Quigley DA, Sjöström M, Zhao SG, Chen WS. Racial variation in the advanced prostate cancer genome. Prostate cancer and prostatic diseases. 2025. PMID: 40164700

Brufsky A, Liu X, Li B, McRoy L, Chen C, Layman RM, Rugo HS. Treatment with palbociclib and an aromatase inhibitor for people with hormone receptor-positive/ human epidermal growth factor receptor 2-negative metastatic breast cancer that has spread to the lungs or liver: a plain language summary. Future oncology (London, England). 2025. PMID: 40159782

Chi KN, Rathkopf D, Smith MR, Efstathiou E, Attard G, Olmos D, Lee JY, Small EJ, Pereira de Santana Gomes AJ, Roubaud G, Saad M, Zurawski B, Sakalo V, Mason GE, Francis P, Wang G, Wu D, Diorio B, Lopez-Gitlitz A, Sandhu S. A plain language summary of the results from the MAGNITUDE study assessing how effective and how safe niraparib and abiraterone acetate with prednisone is in patients with metastatic castration-resistant prostate cancer. Future oncology (London, England). 2025. PMID: 40159790

Kotecha RR, Doshi SD, Knezevic A, Jacobi R, Woo HJ, Aggen DH, McHugh DJ, Shah NJ, Carlo MI, Keegan NM, Gayadin Y, Chaim J, Donoghue MTA, Iyer G, Lee CH, Feldman DR, Motzer RJ, Voss MH. A Phase 1b/2 Study of Talazoparib and Axitinib in Patients with Advanced Clear-cell Renal Cell Carcinoma. European urology oncology. 2025. PMID: 40158923

Bardia A, Pistilli B, Rugo H. Reply to: Assessing Clinical Utility of Datopotamab Deruxtecan Versus Chemotherapy for Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40153734

Batchu SA, Ma Y, Yom S, Heaton C, Algazi A. CRE25-035: Vascular Endothelial Growth Factor Inhibitor-Induced Radiation Recall Tracheitis in a CASTLE Carcinoma of the Thyroid Patient. Journal of the National Comprehensive Cancer Network : JNCCN. 2025. PMID: 40154357

Middha P, Thummalapalli R, Quandt Z, Balaratnam K, Cardenas E, Falcon CJ, Margaret Lung Group P, Gubens MA, Huntsman S, Khan K, Li M, Lovly CM, Patel D, Zhan LJ, Liu G, Aldrich MC, Schoenfeld A, Ziv E. Germline prediction of immune checkpoint inhibitor discontinuation for immune-related adverse events. Journal for immunotherapy of cancer. 2025. PMID: 40154961

Wang M, Jutras G, Cullaro G, Dhruva A, Lai JC. Patterns of dietary supplement use among United States patients with steatotic liver disease: Vitamins, minerals and botanicals. World journal of hepatology. 2025. PMID: 40177193

Unterrainer LM, Farolfi A, Grogan T, Hotta M, Djaileb L, Gafita A, Sonni I, Rettig MB, Rosar F, Ezziddin S, Denis CS, de Kouchkovsky I, Aggarwal R, Emmett L, Hope TA, Czernin J, Calais J. Early changes of PSMA PET expression after initiation of androgen receptor signaling inhibitors in CRPC: an international multicenter retrospective study. European journal of nuclear medicine and molecular imaging. 2025. PMID: 40137974

Perrot A, Facon T, Plesner T, Usmani SZ, Kumar S, Bahlis NJ, Hulin C, Orlowski RZ, Nahi H, Mollee P, Ramasamy K, Roussel M, Jaccard A, Delforge M, Karlin L, Arnulf B, Chari A, He J, Ho KF, Van Rampelbergh R, Uhlar CM, Wang J, Kobos R, Gries KS, Fastenau J, Weisel K. Erratum: Health-Related Quality of Life in Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: Findings From the Phase III MAIA Trial. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40138624

Aggarwal RR, Vuky J, VanderWeele D, Rettig M, Heath EI, Quigley D, Huang J, Chumber A, Cheung A, Foye A, Leung S, Abbey J, Dorr A, Nasoff M, Hunter J, Wang S, Flavell RR, Fong L, Liu B, Small EJ. Phase I, First-in-Human Study of FOR46 (FG-3246), an Immune-Modulating Antibody-Drug Conjugate Targeting CD46, in Patients With Metastatic Castration-Resistant Prostate Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 2025. PMID: 40138611

Yoo C, Ueno M, Klümpen HJ, Kelley RK, Vogel A, Furuse J, Ren Z, Yau T, Chan SL, Ozaka M, Oh SC, Gu S, Park JO, Valle JW, Edeline J, Kim JG, Kamble S, Norquist JM, Yu L, Malhotra U, Finn RS. Health-related quality of life in participants with advanced biliary tract cancer from the randomized phase III KEYNOTE-966 study. Journal of hepatology. 2025. PMID: 40154623

Short NJ, Aldoss I, DeAngelo DJ, Konopleva M, Leonard J, Logan AC, Park J, Shah B, Stock W, Jabbour E. Clinical use of measurable residual disease in adult ALL: recommendations from a panel of US experts. Blood advances. 2025. PMID: 39853316

Loibl S, Martin M, Bonnefoi H, Untch M, Kim SB, Bear HD, García-Sáenz JA, Melé Olivé M, Mc Carthy N, Gelmon K, Kelly CM, Im SA, Reimer T, Martinez-Janez M, Zhang Z, Toi M, Provencher L, Rugo HS, Gnant M, Makris A, Antón Torres A, Hirmas N, Holtschmidt J, Nekljudova V, Marmé F. Final survival results from the PENELOPE-B trial investigating palbociclib versus placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after neoadjuvant chemotherapy-PENELOPE-B. Annals of oncology : official journal of the European Society for Medical Oncology. 2025. PMID: 40139460

Tolani MA, Agbo CA, Paciorek A, Umar SS, Ojewola RW, Mohammed F, Kaninjing E, Ahmed M, DeBoer R. Quality of Care and Survival Outcomes Among Patients With Clinically Localized Prostate Cancer in Nigeria. JCO global oncology. 2025. PMID: 40127382

Decker M, Huang BJ, Ware T, Boone C, Tang M, Ybarra J, Ballapuram AC, Taran KA, Chen PY, Amendáriz M, Leung CJ, Harris M, Tjoa K, Hongo H, Abelson S, Rivera J, Ngo N, Herbst DM, Suciu RM, Guijas C, Sedighi K, Andalis T, Roche E, Xie B, Liu Y, Smith CC, Stieglitz E, Niphakis MJ, Cravatt BF, Shannon K. In vivo validation of the palmitoylation cycle as a therapeutic target in NRAS-mutant cancer. bioRxiv : the preprint server for biology. 2025. PMID: 40166265

Olazagasti C, Celi CV, Mahtani A, Velazquez AI, Kiel L, Sridhar A, Horiguchi M, Gonzalez M, Bernabe C, Abioye O, Dizman N, Florez N. Going Back Home: Understanding the Challenges and Discrimination of Early and Mid-Career International and Puerto Rican Medical Graduates in Oncology Fields in the United States. JCO global oncology. 2025. PMID: 40112258

Mian H, Martin TG, Pond GR, Asoori S, Popat R, Kastritis E, Martinez-Lopez J, Abdallah N, Chhabra S, Parrondo R, Ailawadhi S, Dimopoulos MA, Yong K, Durie BG, Usmani SZ, Lin Y, Tan CR. Outcomes of frailty subgroups of older adults (age ≥ 70) treated with teclistamab: an International Myeloma Foundation immunotherapy database real-world analysis. Leukemia. 2025. PMID: 40113913